Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2004 | Editorial

Translational research using the sodium/iodide symporter in imaging and therapy

Authors: June-Key Chung, Joo Hyun Kang

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2004

Excerpt

The specific accumulation of iodine in the thyroid gland was first identified in 1915, and its utilisation in clinical medicine led to the birth of nuclear medicine. The thyroid gland concentrates iodide by a factor of 20–40 with respect to its plasma level [1]. Radioiodines were first used as tracers of thyroid function, and subsequently for the treatment of hyperthyroidism and benign thyroid diseases. In addition, evidence that iodine transport features in thyroid cancer cells provided a basis for the use of radioiodine in the diagnosis and treatment of thyroid cancer [2]. However, the mechanism of iodine specificity was determined only recently. Iodine enters thyroid cells via a specific transporter, the sodium/iodide symporter (NIS), the gene of which was identified in 1996 [2]. The driving force of iodide uptake is the transmembrane concentration gradient of sodium ion, which is generated and maintained by sodium-potassium ATPase. NIS is an intrinsic membrane protein with 13 transmembrane domains. …

Vieja ADL, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000; 80:1083–1105.PubMed

Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379:458–460.PubMed

Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, Bidart JM. Na+/I− symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 1998; 83:4102–4106.PubMed

Kim S, Chung J-K, Shin JH, Min HS, Kang JH, So Y, Lee DS, Park SH, Lee MC. Expression pattern of N-Ras oncogene, glucose transporter-1 gene and thyroid specific genes in papillary thyroid carcinoma [abstract]. J Nucl Med 2003; 44:41p.

Chung J-K, So Y, Lee JS, Choi CW, Lim SM, Hong SW, Youn YK, Lee MC, Cho BY. Value of FDG PET in papillary thyroid carcinoma with negative¹³¹I whole-body scan. J Nucl Med 1999; 40:986–992.

Min J-J, Chung J-K, Lee YJ, Jeong JM, Lee DS, Jang JJ, Lee MC, Cho BY. Relationship between expression of the sodium/iodide symporter and¹³¹I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001; 28:639–645.PubMed

Haberkorn U, Henze M, Altmann A, Jhiang S, Morr I, Mahmut M, Peschke P, Kubler W, Debus J, Eisenhut M. Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 2001; 42:317–325.PubMed

Lee YJ, Chung J-K, Shin JH, Kang JH, Jeong JM, Lee DS, Lee MC. Animal model of a human anaplastic thyroid cancer cell line, ARO-N, expressing sodium/iodide symporter [abstract]. J Nucl Med 2002; 43:119p.

Mandell RB, Mandell LZ, Link CJ Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999; 59:661–668.PubMed

10.

Boland A, Ricard M, Opolon P, Bidart JM, Yeh P, Filetti S, Schlumberger M, Perricaudet M. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000; 60:3484–3492.PubMed

11.

Cho JY, Shen DH, Yang W, Williams B, Buckwalter TL, La Perle KM, Hinkle G, Pozderac R, Nagaraja R, Barth RE, Jhiang SM. In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral glioma. Gene Ther 2002; 9:1139–1145.CrossRefPubMed

12.

Huang M, Batra RK, Kogai T, Lin YQ, Hershman JM, Lichtenstein A, Sharma S, Zhu LX, Brant GA, Dubinett SM. Ectopic expression of the thyroperoxidase gene augment radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 2001; 8:612–618.CrossRefPubMed

13.

Spitzweg C, O’Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000; 60:6526–6530.PubMed

14.

Jeong JM, Chung J-K. Therapy with¹⁸⁸Re-labeled radiopharmaceuticals: an overview of promising results from initial clinical trials. Cancer Biother Radiopharm 2003; 18:707–717.CrossRefPubMed

15.

Jeong HJ, Chung J-K, Lee YJ, Shin JH, Yeo JS, Lee DS, Lee MC. All-trans retinoic acid enhances expression of transfected sodium/iodide symporter gene in thyroid cancer cells more than in non-thyroid cancer cells [abstract]. J Nucl Med 2002; 43:133p.

16.

Lee YJ, Chung J-K, Kang JH, Shin JH, Kim KI, Oh HJ, Kim YH, So Y, Jeong JM, Lee DS, Lee MC. p53 gene enhanced the effect of radionuclide gene therapy using NIS [abstract]. Mol Imaging 2003; 2:241.

17.

Gambhir SS, Barrio JR, Phelps ME, Iyer M, Namavari M, Sayamurthy N, Wu L, Green LA, Bauer E, MacLaren DC, Nguyen K, Berk AJ, Cherry SR, Hershman HR. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci USA 1999; 96:2333–2338.CrossRefPubMed

18.

Shin JH, Chung J-K, Lee YJ, Kim KI, Kim CW, Jeong JM, Lee DS, Lee MC. Feasibility of sodium/iodide symporter gene as a new imaging reporter gene: comparison with HSV1-tk. Eur J Nucl Med Mol Imaging 2004; in press. DOI 10.1007/s0025900313948.

19.

Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann V, Finn R, Humm J, Larson S, Sadelain M, Blasberg R, Gelovani Tjuvajev J. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A 2001; 98:9300–9305.CrossRefPubMed

20.

Kim KI, Chung JK, Kang JH, Lee YJ, Shin JH, Oh HJ, Jeong JM, Lee DS, Lee MC. Evaluation of endogenous p53 gene expression using sodium iodide symporter as an imaging reporter gene [abstract]. J Nucl Med 2003; 44:28p.

21.

So MK, Chung JK, Kang JH, Lee YJ, Shin JH, Kim KI, So Y, Jeong JM, Lee DS, Lee MC. Monitoring the response of retinoic acid with dual imaging reporter gene, sodium/iodide symporter and luciferase [abstract]. Mol Imaging 2003; 2:256.

22.

Shin JH, Chung JK, Kang JH, Lee YJ, Kim KI, Oh HJ, Kim YH, So MK, Jeong JM, Lee DS, Lee MC. Non-invasive monitoring of adriamycin treatment on cancer cells with dual imaging reporter gene, sodium iodide symporter and luciferase [abstract]. J Nucl Med 2003; 44:28p.

23.

Shin JH, Chung J-K, Roh JK, Lee YJ, Kang JH, Lee DS, Kim KI, Kim MK, Kim DE, Jeong JM, Lee MC. Monitoring of neural stem cell using sodium/iodide symporter gene [abstract]. J Nucl Med 2002; 43:238p.

Title: Translational research using the sodium/iodide symporter in imaging and therapy
Authors: June-Key Chung
Joo Hyun Kang
Publication date: 01-06-2004
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2004
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-004-1475-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Translational research using the sodium/iodide symporter in imaging and therapy

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2004

Requirements for clinical PET: remarks on the current situation in central Europe

Scientific production and impact of nuclear medicine in Europe: how do we publish?

Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology

DMSA study performed during febrile urinary tract infection: a predictor of patient outcome?

Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH?

Use of a standardized uptake value for parametric in vivo imaging of benzodiazepine receptor distribution on [11C]flumazenil brain PET